Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

LEGEND-D Logo

A diagram showing the randomisation options for the LEGEND-D Trial

Open image in High Definition

STUDY OVERVIEW

Type 1 diabetes (T1D) affects around 400,000 people in the UK.  It is caused by near-complete loss of insulin-producing cells in the pancreas. It can be challenging to achieve good control of blood glucose throughout the day, in part because of impaired release of hormones other than insulin, such as glucagon.

Glibenclamide and dapagliflozin are medications normally used in the management of type 2 diabetes. They work by increasing the amount of insulin released by the pancreatic beta-cells and helping the body dispose of glucose via the kidneys, respectively.

The LEGEND-D trial aims to find out whether low doses of glibenclamide or a single dose of dapagliflozin could have a new role in T1D by restoring appropriate glucagon release.

STUDY DESIGN

The LEGEND-D trial is a pilot, randomised cross-over, single-centre, non-blinded, clinical trial which will recruit 20 people with T1D and a control group of 10 people without diabetes. Those with T1D  will receive a liquid form of glibenclamide and later a single tablet of dapagliflozin, and undergo 5 controlled hypoglycaemia challenges; the control group without diabetes will not receive any medication and will undergo one hypoglycaemia challenge. All trial activities will be conducted by the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM) Clinical Research Unit (CRU) at the Churchill Hospital.

AIMS

PRIMARY:

To determine whether treating people with T1D for 14-18 days with glibenclamide at 0.3mg, 0.6mg or 3mg daily can increase plasma glucagon levels during induced hypoglycaemia compared to before treatment.

SECONDARY:

To compare changes in a) plasma glucagon and b) plasma somatostatin before and after administration of a single dose of dapagliflozin in T1D participants to that of participants without diabetes.

STUDY TEAM

Chief Investigator: Ioannis Spiliotis

Co-Investigators: Patrik Rorsman and Amanda Adler

Trial Manager: Nkemjika Abiakam

 

SPONSOR & FUNDER

Sponsor: University of Oxford

Funder: The Leona M. and Harry B. Helmsley Charitable Trust

CONTACT US

Tel: +44 (0)1865857244

Email: legend-d@dtu.ox.ac.uk

About Diabetes

Find out about diabetes, key facts and figures, and how it is currently treated.

About Clinical Research

Find out more about what researchers do and how trials are carried out.

Get Involved

Find out how to take part in our studies.